{"lc": {"ivermectin-can-kill-covid-19-within-48-hours-monash-university-study-finds": {"story_link": "https://www.thepharmaletter.com/article/ivermectin-can-kill-covid-19-within-48-hours-monash-university-study-finds", "user_code": "GOLD_32", "age_group": "21_30", "agreed": true, "close_date_time": "2021-11-8 16:26:55", "close_timestamp": 1638980815077, "created": "08/12/2021 16:26:56", "department": "Computing", "disability": false, "ease": 4, "environment": "production", "experiment_date_datepicker": "2021-12-08", "gender": "female", "id": "dcceb22e-2b38-42a8-9caa-00358570f0f7", "open_date_time": "2021-11-8 16:20:9", "open_timestamp": 1638980409609, "story_date": "2020-04-21 00:00:00", "story_source": "tpl", "story_title": "Ivermectin can kill COVID-19 within 48 hours', Monash University study finds", "summary": "A study about how an already existing drug is able to kill the corona virus within 48 hours. The FDA also approved a drug that can kill other viruses such as HIV.", "task_condition": "text", "task_key": "ivermectin-can-kill-covid-19-within-48-hours-monash-university-study-finds", "task_level": "under_graduate_year_2", "time_taken_in_seconds": 405468, "what": "FDA, COVID-19, interactions between drugs and covid, The vaccine", "when_happened": "current_month", "where_location": "Australia", "who": "Peter Doherty, Dr Kylie Wagstaff", "why": "its informative, helpful"}, "challenges-expected-for-novavax-covid-19-vaccine-in-usa": {"story_link": "https://www.thepharmaletter.com/article/challenges-expected-for-novavax-covid-19-vaccine-in-usa", "user_code": "GOLD_32", "age_group": "21_30", "agreed": true, "close_date_time": "2021-11-8 16:37:47", "close_timestamp": 1638981467300, "created": "08/12/2021 16:37:47", "department": "Computing", "disability": false, "ease": 2, "environment": "production", "experiment_date_datepicker": "2021-12-08", "gender": "female", "id": "97b2ef91-6a7f-4e56-831a-a9457eb2413f", "open_date_time": "2021-11-8 16:32:44", "open_timestamp": 1638981164549, "story_date": "2021-06-23 00:00:00", "story_source": "tpl", "story_title": "Challenges expected for Novavax' COVID-19 vaccine in USA", "summary": "The Novavax' COVID-19 vaccine in USA has caused a few issues such as supplies decreasing, larger doses required to improve efficiency of the vaccine etc. It also discusses how it effects new variants.", "task_condition": "viz", "task_key": "challenges-expected-for-novavax-covid-19-vaccine-in-usa", "task_level": "under_graduate_year_2", "time_taken_in_seconds": 302751, "what": "COVID-19, The vaccine,", "when_happened": "current_month", "where_location": "The USA", "who": "Researchers", "why": "The impact of the vaccine"}, "australian-gps-urged-to-prescribe-ivermectin-triple-therapy-to-fight-covid-19": {"story_link": "https://www.thepharmaletter.com/article/australian-gps-urged-to-prescribe-ivermectin-triple-therapy-to-fight-covid-19", "user_code": "GOLD_32", "age_group": "21_30", "agreed": true, "close_date_time": "2021-11-8 16:32:17", "close_timestamp": 1638981137605, "created": "08/12/2021 16:32:17", "department": "Computing", "disability": false, "ease": 4, "environment": "production", "experiment_date_datepicker": "2021-12-08", "gender": "female", "id": "c33fd26b-5deb-4bc0-9739-4936052bde16", "open_date_time": "2021-11-8 16:27:18", "open_timestamp": 1638980838742, "story_date": "2020-08-20 00:00:00", "story_source": "tpl", "story_title": "Australian GPs urged to prescribe ivermectin triple therapy to fight COVID-19", "summary": "A gastroenterologist named Thomas Borody discovers that a combination of antibiotics and minerals such as zinc could be an alternative way to end the pandemic. He suggests it would save more lives and time rather than waiting for the vaccine ", "task_condition": "text", "task_key": "australian-gps-urged-to-prescribe-ivermectin-triple-therapy-to-fight-covid-19", "task_level": "under_graduate_year_2", "time_taken_in_seconds": 298863, "what": "COVID-19, Vitamins, Antibiotics, The vaccine, Research, Studies", "when_happened": "current_month", "where_location": "Australia", "who": "Thomas Borody", "why": "Informative, Saves time, Helpful"}, "japan-is-first-country-to-approve-covid-19-cocktail-ronapreve": {"story_link": "https://www.thepharmaletter.com/article/japan-is-first-country-to-approve-covid-19-cocktail-ronapreve", "user_code": "GOLD_32", "age_group": "21_30", "agreed": true, "close_date_time": "2021-11-8 16:42:8", "close_timestamp": 1638981728162, "created": "08/12/2021 16:42:08", "department": "Computing", "disability": false, "ease": 1, "environment": "production", "experiment_date_datepicker": "2021-12-08", "gender": "female", "id": "237a57d4-e0e2-4296-8f7e-e5feb478fa3d", "open_date_time": "2021-11-8 16:37:57", "open_timestamp": 1638981477987, "story_date": "2020-07-21 00:00:00", "story_source": "tpl", "story_title": "Japan is first country to approve COVID-19 cocktail Ronapreve", "summary": "Japan approving the COVID-19 antibody cocktail Ronapreve. It treats the infections and reduces symptoms with only some risks.", "task_condition": "viz", "task_key": "japan-is-first-country-to-approve-covid-19-cocktail-ronapreve", "task_level": "under_graduate_year_2", "time_taken_in_seconds": 250175, "what": "cocktail Ronapreve, Japan", "when_happened": "current_month", "where_location": "Japan", "who": "Doctors, Researchers, People in Japan", "why": "informative"}}, "tb": {"pfizer": {"story_term": "pfizer", "user_code": "GOLD_32", "age_group": "21_30", "agreed": true, "close_date_time": "2021-11-8 16:52:52", "close_timestamp": 1638982372702, "created": "08/12/2021 16:52:54", "department": "Computing", "disability": false, "ease": 2, "environment": "production", "experiment_date_datepicker": "2021-12-08", "gender": "female", "id": "f870aa28-5f2f-4531-a7f7-f3cf58a79262", "open_date_time": "2021-11-8 16:42:30", "open_timestamp": 1638981750991, "summary": "Pfizer have announced that the FDA has approved Myfembree as treatment for the management of heavy menstrual bleeding associated with uterine fibroids. Myovant and Pfizer will jointly commercialize the product in the USA. The tablet is expected to be available next month.\r\n\r\nEvidence from public health authorities in the UK suggests that coronavirus vaccines from Pfizer are effective against the Indian variant.\r\n\r\nNew storage conditions for the COVID-19 vaccine from Pfizer have been approved by the UK\u00e2\u0080\u0099s MHRA.The new storage conditions extend the length of time the thawed vaccine can be stored at normal fridge temperatures from five days to 31 days.\r\n\r\nHealth Canada has approved a broader use of Comirnaty, the coronavirus vaccine from Pfizer to include 12 to 15 year olds. While demand for vaccines continues to outstrip supplies in many parts of the world, certain countries have been able to cover a large percentage of their populations in recent months.\r\n\r\n\r\n\r\n", "task_condition": "text", "task_key": "pfizer", "task_level": "under_graduate_year_2", "time_taken_in_seconds": 621711}, "astrazeneca": {"story_term": "astrazeneca", "user_code": "GOLD_32", "age_group": "21_30", "agreed": true, "close_date_time": "2021-11-8 17:5:29", "close_timestamp": 1638983129211, "created": "08/12/2021 17:05:30", "department": "Computing", "disability": false, "ease": 1, "environment": "production", "experiment_date_datepicker": "2021-12-08", "gender": "female", "id": "9a1092cd-67a0-4639-82b2-16b9ef4f9f06", "open_date_time": "2021-11-8 16:53:19", "open_timestamp": 1638982399362, "summary": "Vaccine producers, AstraZeneca, has secured a new approval in Europe, for the adjuvant treatment of certain adults with early-stage non-small cell lung cancer. Public health authorities in the UK suggests that coronavirus vaccines from AstraZeneca, are effective against the Indian variant. However the European Union launched a legal action against AstraZeneca due to the British firm failing to live up to its contractual obligations on vaccine supplies. The European leaders have been frustrated by a slow vaccine rollout. \r\n\r\nThe approval of a FDA emergency use authorisation or AstraZeneca\u00e2\u0080\u0099s COVID-19 will boost confidence and use of the vaccine globally.\r\n\r\nInterim analysis for AZD1222 showed the vaccine to be 76% effective at preventing symptomatic COVID-19. However, initial interim results showed that it was 79% effective.\r\n\r\nIn the latest update on the safety of AstraZeneca\u00e2\u0080\u0099s vaccine, the European Medicines Agency has today announced its conclusion that unusual blood clots with low blood platelets should be listed as very rare side effects However the benefits of the vaccine continue to outweigh the risks for people who receive it. The vaccine is effective at preventing COVID-19 and reducing hospitalisations and deaths.", "task_condition": "viz", "task_key": "astrazeneca", "task_level": "under_graduate_year_2", "time_taken_in_seconds": 729849}}}